DAWN Day One Biopharmaceuticals Holding Co LLC

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

$7.29  +0.07 (0.97%)
As of 05/24/2022 15:59:58 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/23/2009
Outstanding shares:  61,911,929
Average volume:  263,203
Market cap:   $445,765,889
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BLB0YH0

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   1.72
PS ratio:   0.00
Return on equity:   -70.57%
Net income %:   0.00%